MARKHAM, Ontario, June 15, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of June 2023, representing $0.936 per Common Share on an annualized basis.
The dividend will be payable on July 14, 2023 to shareholders of record as at June 30, 2023.
The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.
About Sienna Senior Living
Sienna Senior Living Inc. (TSX:SIA) offers a full range of seniors' living options, including independent living and assisted living under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna's approximately 12,000 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.
For further information, please contact: David Hung Chief Financial Officer & Executive Vice President (905) 489-0258 [email protected]
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...
Product: Kalihim (Philippine Bread Roll)
Issue: Food - Allergen - Egg
Distribution: British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
